candesartan has been researched along with Complications of Diabetes Mellitus in 11 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 5.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen." | 5.14 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Navarro-Cid, J, 2009) |
| "The aim of the research was to evaluate some clinical and hemodynamic characteristics in patients with diabetes mellitus type 1 and type 2 (DM type 1 and DM type 2), to diagnose diabetic retinopathy (DR) on early stage of its development for the correction of the disease by treating with angiotensin II type 1 receptor blocker (AT I)--Candesartan." | 5.13 | [Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus]. ( Kurashvili, GR; Kurashvili, RB; Shelestova, EL; Tsibadze, AD; Tsutskiridze, LR, 2008) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "In candesartan-treated db/db mice (1 mg/kg per day, 4 weeks) increased plasma aldosterone, CYP11B2 expression, and aldosterone secretion were reduced." | 1.38 | Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. ( Briones, AM; Burger, D; Burns, KD; Callera, GE; Corrêa, JW; Gagnon, AM; Gomez-Sanchez, CE; Gomez-Sanchez, EP; He, Y; Nguyen Dinh Cat, A; Ooi, TC; Ruzicka, M; Sorisky, A; Touyz, RM; Yogi, A, 2012) |
| "Diabetes and hypertension are potent risk factors for cerebrovascular disease." | 1.33 | Diabetic brain damage in hypertension: role of renin-angiotensin system. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Matsui, Y; Morinari, M; Shimada, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsutskiridze, LR | 1 |
| Kurashvili, RB | 1 |
| Tsibadze, AD | 1 |
| Kurashvili, GR | 1 |
| Shelestova, EL | 1 |
| Barrios, V | 1 |
| Escobar, C | 1 |
| Calderón, A | 1 |
| Echarri, R | 1 |
| Barrios, S | 1 |
| Navarro-Cid, J | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Briones, AM | 1 |
| Nguyen Dinh Cat, A | 1 |
| Callera, GE | 1 |
| Yogi, A | 1 |
| Burger, D | 1 |
| He, Y | 1 |
| Corrêa, JW | 1 |
| Gagnon, AM | 1 |
| Gomez-Sanchez, CE | 1 |
| Gomez-Sanchez, EP | 1 |
| Sorisky, A | 1 |
| Ooi, TC | 1 |
| Ruzicka, M | 1 |
| Burns, KD | 1 |
| Touyz, RM | 1 |
| Sato, N | 1 |
| Kase, H | 1 |
| Kato, T | 1 |
| Kasai, K | 1 |
| Winkler, G | 1 |
| Jermendy, G | 1 |
| Matos, L | 1 |
| Kario, K | 1 |
| Ishikawa, J | 1 |
| Hoshide, S | 1 |
| Matsui, Y | 1 |
| Morinari, M | 1 |
| Eguchi, K | 1 |
| Ishikawa, S | 1 |
| Shimada, K | 1 |
| Kinugawa, S | 2 |
| Tsutsui, H | 1 |
| Matsushima, S | 1 |
| Ide, T | 1 |
| Inoue, N | 1 |
| Ohta, Y | 1 |
| Yokota, T | 1 |
| Hamaguchi, S | 1 |
| Sunagawa, K | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
5 reviews available for candesartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabe | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
[Diabetic heart disease].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
2 trials available for candesartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2008 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; | 2009 |
4 other studies available for candesartan and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction.
Topics: Adipocytes; Aldosterone; Animals; Benzimidazoles; Biphenyl Compounds; Calcineurin; Cells, Cultured; | 2012 |
Diabetic brain damage in hypertension: role of renin-angiotensin system.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspartic Acid; Benzimidazoles; Biphenyl Compounds; Bl | 2005 |
Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Biphenyl Compounds; Blo | 2007 |
[Treatment of hypertension. Effectiveness of sartans is far from exhausted].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |